Actelion launches Zavesca in the UK and Ireland
This article was originally published in Scrip
Executive Summary
Actelion has launched its Zavesca (miglustat) in the UK and Ireland for the extended indication of treating the progressive neurological manifestations of Niemann-Pick type C disease in adults, children and infants.